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Abstract 
Background: Plasma albumin is reduced during inflammation. Obesity, a strong risk factor for type 2 diabetes (T2D), 
is associated with adipose tissue inflammation. However, whether albumin is associated with adipose tissue inflam-
mation and whether it predicts T2D are unclear.
Methods: Adults (predominantly American Indian) from a longitudinal study were included. Macrophage content 
and gene expression related to recruitment/activation were measured from subcutaneous adipose tissue (n = 51). 
The relationship between plasma albumin and adiposity (dual-energy X-ray absorptiometry or hydrodensitometry), 
glucose (oral glucose tolerance test), insulin action (hyperinsulinemic-euglycemic clamp), and insulin secretion (intra-
venous glucose tolerance test) were evaluated (n = 422). Progression to T2D was evaluated by Cox regression (median 
follow-up 8.8 years; 102 progressors).
Results: Albumin was associated with macrophage markers including C1QB (r = − 0.30, p = 0.04), CSF1R (r = − 0.30, 
p = 0.03), and CD11b (r = − 0.36, p = 0.01). Albumin was inversely associated with body fat percentage (r = − 0.14, 
p = 0.003), fasting plasma glucose (r = − 0.17, p = 0.0003), and 2 h plasma glucose (r = − 0.11, p = 0.03), and was 
reduced in impaired glucose regulation compared with normal glucose regulation (mean ± SD: 39.4 ± 3.6 g/l and 
40.1 ± 3.9 g/l, respectively; p = 0.049). Albumin predicted T2D, even after adjustment for confounders (HR, 0.75; 95% CI 
0.58–0.96; p = 0.02; per one SD difference in albumin).
Conclusions: Reduced albumin is associated with an unfavorable metabolic profile, characterized by increased adi-
pose tissue inflammation, adiposity, and glucose, and with an increased risk for T2D.
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Background
Albumin is the most abundant soluble protein in plasma 
or serum, accounting for about 50% to 60% of total pro-
tein [1]. It is synthesized nearly exclusively by the liver 
and about half is degraded by muscle, liver, and kidneys. 
Albumin is a versatile protein with a variety of biological 
roles such as maintaining plasma oncotic pressure, pro-
viding > 50% of total antioxidant in normal plasma, and 
serving as the primary carrier protein for non-esterified 
fatty acids [1]. In addition, albumin binds and transports 
various other endogenous molecules (e.g. metal ions, 
heme, thyroxine, bilirubin) [1]. Although historically 
linked to malnutrition and protein intake, there is now 
considerable evidence that low circulating albumin is an 
indicator of an inflammatory process [1, 2].
Although type 2 diabetes (T2D) was traditionally 
regarded as a metabolic disease with a defect in insulin 
action preceding or occurring concurrently with pancre-
atic beta-cell failure [3]. it is now well-recognized that 
chronic inflammation is a pathogenic component of T2D 
and obesity, a strong risk factor for T2D [4]. Diminished 
insulin action is characterized by chronic inflammation 
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[5]. There is evidence for inflammation as a risk factor 
for development of T2D specifically in American Indians 
from a community in the southwestern United States, 
a group which has a high incidence of T2D and obesity 
[6, 7]. In this population, adipose tissue markers of mac-
rophage activation were associated with insulin action 
[8], and elevated peripheral leukocyte count predicted 
worsening insulin action and the development of T2D 
[9]. It is unclear whether circulating albumin is associ-
ated with either macrophage content or activation within 
adipose tissue.
There have been a limited number of longitudinal stud-
ies that have reported the association between circulat-
ing albumin and T2D risk [10–14]. Albumin is a negative 
acute-phase reactant and lower albumin indicates greater 
inflammation [15]. Thus, lower circulating albumin 
might be expected to be associated with increased risk of 
T2D as a few studies have demonstrated [10, 11]. These 
results are not consistent as others have shown no associ-
ation [11, 12], or association between lower albumin and 
lower risk of T2D [13]. However, to our knowledge, none 
of these studies reported association between albumin 
and reference measures of insulin action and secretion or 
accounted for these as potential confounders.
To further elucidate the role of circulating albumin in 
T2D, we conducted a series of related investigations in 
American Indians who were from a community in the 
Southwestern United States [6, 7] and were without dia-
betes. First, we hypothesized that adipose tissue inflam-
mation might influence plasma albumin concentrations. 
Therefore, we evaluated the association between circulat-
ing albumin and macrophage content/activation in sub-
cutaneous adipose tissue to characterize albumin as an 
indicator of obesity-induced inflammation. After finding 
that lower albumin was associated with several markers 
of greater adipose tissue inflammation, we hypothesized 
that lower plasma albumin would be associated with 
more unfavorable metabolic profile. So, in a larger group 
from this population, we evaluated the associations 
between albumin with body composition, glucose and 
insulin concentrations from the oral glucose tolerance 
test (OGTT), and reference measures of insulin action 
and secretion [insulin-stimulated glucose disposal (M) 
by the hyperinsulinemic-euglycemic clamp (HIEC) and 
acute insulin response (AIR) by the intravenous glucose 
tolerance test (IVGTT), respectively]. Third, we hypoth-
esized that individuals with lower albumin are at greater 
risk of developing T2D.
Methods
Study population
Between 1965 and 2007, individuals from an Ameri-
can Indian community in Arizona participated in a 
longitudinal study of diabetes and its complications [6]. 
Members at least 5 years old were invited for outpatient 
research examinations every 2  years which included an 
OGTT. Some members also participated in a detailed 
inpatient metabolic study to assess determinants of T2D 
as previously described [16].
For the current study, we included only those who par-
ticipated in the detailed inpatient metabolic study, non-
pregnant adults (age ≥ 18 years) without T2D at baseline, 
and participants who were at least 6/8 heritage (defined 
below) American Indian from the southwest. To evalu-
ate the association between plasma albumin with M and 
AIR, study visits from which the first HIEC and IVGTT 
were available were used for the cross-sectional analysis. 
Diabetes at follow-up and diagnosis date was based on 
OGTT values at the time of the visit or review of medical 
records. Classification was according to the 2003 Ameri-
can Diabetes Association criteria [17]. Written informed 
consent was obtained from all participants. Both stud-
ies were approved by the Institutional Review Board of 
National Institute of Diabetes and Digestive and Kidney 
Diseases.
Anthropometrics, body composition, and fixed factors
Body mass index (BMI) (kg/m2) was calculated by meas-
ured height and weight. Heritage for this particular 
southwestern American Indian community was deter-
mined by self-report and classified into those with full 
heritage (8/8 heritage) and those with mixed heritage 
(6/8 or 7/8 heritage) and included as a covariate since 
heritage was previously associated with greater risk of 
T2D [18].
Body composition was assessed by hydrodensitometry 
[19] or by total body dual-energy X-ray absorptiometry 
(DPX-L; Lunar Radiation, Madison, WI). The absorpti-
ometry measures were converged to comparable hydro-
densitometry values, using previously derived equations 
[20] to calculate percentage of body fat (%fat).
Oral and intravenous glucose tolerance tests
A 75-g OGTT was performed during baseline and fol-
low-up visits. For the IVGTT, a 25-g intravenous glucose 
bolus injection over 3 min was administered [21, 22]. AIR 
was calculated as the mean of the 3, 4, 5 min insulin con-
centrations minus the fasting concentration [22].
Hyperinsulinemic‑euglycemic clamp
The HIEC occurred after an overnight fast where-
upon a primed continuous insulin infusion (40 mU/m2/
min based by body surface area) was administered for 
100  min and 20% dextrose was infused at various rates 
to maintain a 5.6  mmol/l plasma glucose concentra-
tion [23]. M was determined from the last 40 min of the 
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insulin infusions while correcting for the steady-state 
insulin plasma concentration and endogenous glucose 
production (EGP). The EGP was measured via primed 
[3-3H]-glucose infusions. M was normalized to estimated 
metabolic body size (fat-free mass + 17.7 kg) [24].
Analytic procedures
Plasma glucose concentrations were measured by enzy-
matic methods. Plasma insulin concentrations were 
determined by the Herbert modification [25] of the 
method of Yalow and Berson [26] or automated analyz-
ers (Concept 4, ICN Radiochemicals Inc, Costa Mesa, 
CA; Access, Beckman Instruments). Values from the 
later insulin assays were regressed to the original radio-
immunoassay. Plasma albumin was measured by the 
bromocresol purple method (Monarch Chemistry ana-
lyzer, Instrumentation Laboratory, Lexington, MA; 
DADE Behring Dimension RxL Chemistry analyzer, Sie-
mens Medical Solutions, Malvern, PA) in the hospital 
laboratory.
Fat biopsy, morphological analysis, and real‑time 
quantitative PCR
Subcutaneous adipose tissue was obtained by percuta-
neous needle biopsy of the periumbilical fat depot and 
immediately frozen in liquid nitrogen. Detailed descrip-
tion of the biopsy and measurement of macrophage 
content were previously described [8]. RNA expression 
markers evaluated from frozen adipose tissue included 
CD68, integrin αM (ITGAM)/CD11b, CSF1R, LEP/
leptin, ICAM1, CCL-2/MCP-1, plasminogen activator 
inhibitor type-1 (PAI-1), hypoxia-inducible factor-1α 
(HIF-1a), vascular endothelial growth factor (VEGF), 
C1QB, S100A8, tumor necrosis factor (TNF), matrix 
metalloproteinase-9 (MMP9), and CD11c. Methods 
involving real-time quantitative PCR were previously 
described in detail [8].
Statistical analyses
Statistical analyses were performed using SAS software 
(SAS Version 9.4 or Enterprise Guide 7.13; SAS Insti-
tute, Cary, North Carolina). Non-normally distributed 
data were log transformed (e.g. M and AIR). Pearson or 
Spearman correlation analysis was used to quantify the 
relationships between plasma albumin and variables 
of interest before and after adjustment for covariates. 
For comparison of participant characteristics, unpaired 
t-test, Wilcoxon rank-sum, and Chi squared tests were 
used where appropriate. To assess albumin as a predic-
tor of incident T2D, a Cox model was used to calculate 
hazard ratios for development of diabetes, adjusting for 
baseline age, sex, %fat, heritage, M, AIR, and fasting and 
2  h-PG concentrations. All analyses used only baseline 
measurements because our primary interest was the 
clinically-relevant predictive value of plasma albumin 
at a single time-point for subsequent development of 
T2D. Proportional hazards assumptions were checked by 
assessment of plots of log[− log(survival)] versus log of 
survival time and inclusion of a time-dependent interac-
tion term. The follow-up time was truncated to 15 years 
to satisfy the proportionality assumption. To facilitate 
comparisons, continuous variables including were stand-
ardized (i.e. mean = 0 and SD = 1) and the hazard ratio 
was reported per SD. Cumulative incidence of diabetes 
was estimated from the Kaplan–Meier method for par-
ticipants above and below the median. The association 
between plasma albumin and residual adipose tissue 
expression was performed, adjusting for potential con-
founders (e.g. age, sex, %fat), using linear regression. An 
alpha level of 0.05 was chosen for analyses.
Results
Baseline participant characteristics for the cross-sec-
tional, prospective, and adipose tissue analyses are shown 
in Table 1.
Subcutaneous adipose tissue analysis
In the group that underwent adipose tissue biopsies, 
plasma albumin was associated with %fat (r = − 0.41, 
p = 0.003  l, adjusted for age and sex, Fig.  1a). Plasma 
albumin was not associated with macrophage con-
tent by immunohistochemical analysis. In simple cor-
relations, CD68 and CCL2 were correlated with plasma 
albumin (r = − 0.37, p = 0.009 and r = − 0.38, p = 0.007, 
respectively), but not after adjusting for age, sex, and 
%fat. Plasma albumin was inversely correlated with gene 
expression markers of adipose tissue macrophage con-
tent, CSF1R (r = − 0.30, p = 0.03) and CD11b (r = − 0.36, 
p = 0.01), adjusted for age, sex, and %fat (Fig.  1b, c, 
respectively). C1QB, a marker of adipose tissue mac-
rophage activation and a part of the classical complement 
system mostly expressed in the stromal fraction of adi-
pose tissue [27] and involved in eliciting a macrophage 
phenotype promoting clearance of apoptotic cells [28], 
was also associated with plasma albumin (r = − 0.30, 
p = 0.04; adjusted for age, sex, and %fat; Fig.  1d). These 
associations indicate that plasma albumin may be reflect-
ing inflammation within adipose tissue.
Cross‑sectional analysis
Plasma albumin declined with increasing age (r = − 0.14, 
p = 0.004; adjusted for sex and %fat). Men had 
greater mean plasma albumin compared with women 
(mean ± SD: 41.1 ± 4.2 g/l and 38.2 ± 4.5 g/l, respectively; 
p < 0.0001). These sex differences did not persist after 
adjusting for age and %fat (p > 0.05). Participants of full 
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heritage had lower plasma albumin compared with those 
less than full heritage (mean ± SD: 39.6 ± 4.1  g/dl and 
41.0 ± SD 4.4 g/dl, respectively; p < 0.0001). After adjust-
ing for age, sex, and %fat, this difference was largely atten-
uated but remained significantly different (mean ± SD: 
Full 39.9 ± 4.1 g/l; Non-full 39.8 ± 4.7 g/l; p = 0.01).
Plasma albumin was inversely associated with weight 
(r = − 0.21, p < 0.0001), BMI (r = − 0.33, p < 0.0001), %fat 
(r = − 0.37, p < 0.0001). Controlling for age, sex, heritage, 
M, AIR, and FPG and 2  h-PG concentrations attenu-
ated but did not abolish the inverse association between 
albumin and %fat (r = − 0.14, p = 0.003). Plasma albumin 
was associated with increasing insulin action (r = 0.10, 
p = 0.045; adjusted for age and sex), but not significantly 
correlated after further adjusting for %fat (p > 0.05). 
Plasma albumin, controlling for age and sex, was not 
associated with AIR or EGP during the basal and insulin-
infusion periods.
Plasma albumin was reduced in participants with 
impaired glucose regulation (IGR) compared with those 
with normal glucose regulation (NGR) (mean ± SD: 
38.5 ± 4.0 g/l and 40.6 ± 4.2 g/l, respectively; p < 0.0001). 
The difference remained when adjusted for age, sex, 
%fat, and heritage (mean ± SD: IGR 39.4 ± 3.6  g/l; NGR 
40.1 ± 3.9  g/l; p = 0.049). Lower plasma albumin was 
associated with higher FPG (r = − 0.29, p < 0.0001). The 
association between plasma albumin and FPG persisted 
when adjusting for age, sex, heritage, %fat, M, and AIR 
(r = − 0.17, p = 0.0003). Reduced albumin was also asso-
ciated with higher 2h-PG (r = − 0.25, p < 0.0001) and the 
association remained when controlling for age, sex, %fat, 
heritage, M, and AIR (r = − 0.11, p = 0.03). Plasma albu-
min was inversely associated with fasting plasma insulin 
during the OGTT (r = − 0.10, p = 0.049; adjusted for age 
and sex) but the association did not persist after further 
adjustment for %fat.
Prospective analysis
Of the 422 subjects in the cross-sectional analysis, 379 
(90%) had follow-up over a median of 8.8  years [Inter-
quartile Range (IQR), 5.5 to 12.2  years] and 102 devel-
oped T2D (Table  1). In the Cox models, continuous 
variables [plasma albumin, age, %fat, M (log), AIR (log), 
FPG, and 2h-PG] were standardized and expressed per 
one SD change in these variables. Reduced albumin pre-
dicted progression to T2D in univariate analysis (HR 
0.63; 95% CI 0.51–0.78, p < 0.0001) and remained predic-
tive of T2D in different multivariate models using Cox 
Table 1 Baseline characteristics
NGR normal glucose regulation, IGR impaired glucose regulation, EMBS estimated metabolic body size = fat-free mass + 17.7, EGP endogenous glucose production
a Data reported as the median (IQR; 25th to 75th percentile)
b Data reported as the mean (SD)
c  < 0.001
d  < 0.05
e  < 0.01
f  < 0.0001
Adipose tissue Cross‑sectional analysis Prospective analysis
Non‑progressors Progressors
n 51 422 277 102
Male, n (%) 33 (65) 243 (58) 171 (62) 43 (42)c
Age (years)a 31 (23, 39) 27 (23, 32) 26 (22, 31) 28 (24, 32)d
Full heritage, n (%) 37 (73) 345 (82) 217 (78) 92 (90)e
Body weight (kg)b 94 (24) 94 (23) 91 (21) 102 (22)f
BMI (kg/m2)b 33 (8) 34 (8) 33 (7) 38 (7)f
Body fat (%)b 31 (8) 33 (8) 31 (8) 36 (7)f
FPG (mmol/l)b 4.8 (0.5) 5.0 (0.6) 4.9 (0.6) 5.2 (0.6)f
2 h-PG (mmol/l)b 6.5 (1.8) 6.9 (1.8) 6.5 (1.6) 7.9 (1.8)f
NGR/IGR 33/18 265/157 198/79 41/61
Fasting insulin—OGTT (pmol/L)a 155 (89, 272) 153 (76, 271) 139 (69, 236) 236 (132, 382)f
M (mg kg−1EMBS min
−1)a 2.80 (2.41, 3.86) 2.29 (1.99, 2.87) 2.48 (2.11, 3.19) 2.03 (1.86, 2.64)f
AIR (pmol/l)a 1347 (860, 2309) 1403 (917, 2132) 1535 (1000, 2215) 1264 (785, 1833)d
EGP—basal (mg kg−1EMBS min
−1)b 1.95 (0.35) 2.45 (0.40) 1.90 (0.24) 1.91 (0.26)
EGP—insulin (mg kg−1EMBS min
−1)a 0.27 (0, 0.60) 0.25 (0, 0.58) 0.19 (0, 0.56) 0.39 (0.15, 0.70)f
Albumin (g/l)b 39.6 (4.2) 39.8 (4.2) 40.2 (4.3) 38.7 (3.6)f
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regression (Table 2). In the full model adjusting for age, 
sex, heritage, %fat, M, AIR, FPG, and 2h-PG, higher albu-
min was protective for progression to T2D (HR 0.75; 95% 
CI 0.58–0.96 (Table  2). Cumulative incidence rates of 
T2D at 10 years were 31% and 16% for the groups below 
and above the median plasma albumin, respectively, 
adjusting for the same covariates as the full Cox model. 
Results were consistent in sensitivity analysis restricting 
participants to those who were full heritage.
Discussion
In this study, complementary analyses delineated the role 
of plasma albumin in obesity and T2D. Among healthy 
adult participants, reduced albumin, independent of 
%fat, was found to be associated with several expres-
sion markers of adipose tissue inflammation, indicating 
that albumin may be reflecting an immunological milieu 
which may be contributing to risk of T2D. Furthermore, 
reduced albumin was associated with higher %fat and 
higher plasma glucose concentration. Moreover, the 
current study, involving a large sample in a well-defined 
population with detailed reference measurements of 
important risk factors for T2D (e.g. %fat, insulin action, 
and insulin secretion), also demonstrated that lower 
albumin predicts the development of T2D even when 
accounting for these confounders.
In cross-sectional studies, those with T2D have lower 
circulating albumin [29, 30] compared to those without 
T2D. The current study, demonstrating that lower albu-
min is associated with higher glucose concentrations 
and elevates risk of incident T2D, indicates a potential 
mechanism that is both influencing albumin abundance 
and contributing to the pathogenesis of T2D. Several 
possibilities exist for such a mechanism. First, diabetes 
may result in decreased hepatic albumin synthesis [31, 
32]. Second, albumin could be reduced via mechanisms 
related to formation of glycated albumin [1]. Glycated 
albumin has aberrant ability to bind various ligands and 
acts as a precursor to advanced glycation end-products, 
leading to oxidative stress and inflammation [1]. Given 
the deleterious consequences of glycated albumin, it is 
not surprising that mechanisms to clear glycated albumin 
have evolved. In diabetic rats, renal clearance of albumin 
is enhanced by glycation [33]. Moreover, there is evidence 
that glycated albumin (and other glycated proteins) elic-
its an immunological response that may further reduce 
Fig. 1 Associations between plasma albumin and a body fat percentage (adjusted for age and sex), and b–d gene expression of inflammatory 
markers in adipose tissue (adjusted for age, sex, and body fat percentage). AU, mRNA values normalized using mRNA expression of csnk1d
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albumin. Glycated proteins such as albumin may pre-
sent new immunological epitopes and hence act as neo-
antigens for autoantibody production. Autoantibodies 
against reactive-oxygen species-modified glycated albu-
min has been shown to be present in persons with type 
1 and T2D [34]. These autoantibodies with their antigen 
form circulating immune complexes which are predomi-
nantly cleared [35]. Albumin has been recently shown 
to be elevated in these complexes isolated from humans 
with impaired glucose tolerance and T2D [36], and clear-
ance of these complexes would further lower albumin 
levels. Glycated albumin was not measured in this study, 
so its role could not be evaluated. However, there is rea-
son to suspect that relatively increased glycation is occur-
ring among those with low albumin in our study. Higher 
plasma glucose concentrations and lower albumin were 
associated, and glycated albumin is an increasingly recog-
nized marker of glycaemia [37]. Another explanation for 
why higher albumin was protective for T2D may be due 
to the competition between albumin and other plasma 
protein for glycation. Due to albumin’s abundance, higher 
albumin concentration has been shown to protect other 
proteins such as insulin from being glycated [38], which 
has been shown to have diminished biological activity as 
demonstrated by the HIEC procedure [39]. Further stud-
ies are needed to elucidate the mechanism behind the 
association between reduced albumin and increased risk 
for T2D.
A strength of this study is that the relationships 
between albumin and adipose tissue markers of inflam-
mation were examined. This finding points to a potential 
inflammatory source within the body for lower albumin 
concentrations. Although inflammation within other tis-
sues/organs was not evaluated in this study, other known 
co-morbidities associated with lower albumin such as 
infectious or rheumatologic conditions are unlikely given 
that only healthy individuals were studied. The findings, 
that reduced albumin is associated with adipose tis-
sue inflammation and predicts T2D, is consistent with 
chronic low-grade inflammation due to obesity in the 
development of T2D [15].
The current study found that reduced albumin predicts 
incident T2D and was consistent with other prospec-
tive studies in other populations [10, 11]. However, these 
results differ from other studies that show no association 
[11, 12], or association between lower albumin and lower 
risk of T2D [13]. Differences with prior studies could 
explain the different results. First, unlike these prior 
studies, the current study measured adiposity, and insu-
lin action and secretion using reference measures and 
adjusted for these confounders in the models. Second, 
the current study was performed in an American Indian 
population with high rates of obesity and T2D. Though 
the pathophysiology of the development of diabetes in 
this American Indian population mirrors those of other 
populations, it is possible that population differences 
explain the conflicting results.
Several limitations should be acknowledged. First, since 
only baseline albumin and risk factors were evaluated, it 
is possible that accounting for repeated measurements 
over time could alter the association with risk of T2D. 
Second, expression of adipose tissue inflammatory genes 
was available only on a limited number of individuals so 
the ability of these markers to predict T2D could not be 
evaluated and compared with albumin. Third, this was 
an association study, so it cannot be determined whether 
efforts to maintain the abundance of albumin would be 
effective in preventing T2D.
Conclusion
In summary, low albumin was associated with an adverse 
metabolic profile characterized by increased adipos-
ity, plasma glucose concentrations, and adipose tissue 
inflammation. Moreover, reduced albumin increased risk 
for T2D. These findings place albumin within the existing 
paradigm linking obesity-related inflammation and T2D.
Table 2 Cox models for  type 2 diabetes in  relation 
to plasma albumin
Models 1–4 are also adjusted for age, sex and American Indian heritage
Albumin, body fat percentage, M, AIR, and 2h-PG were standardized to a normal 
distribution with SD = 1
AIR acute insulin response, FPG fasting plasma glucose, 2h-PG 2 h plasma 
glucose
Model adjustments HR (95% CI) p value
Unadjusted model
 Albumin 0.63 (0.51, 0.78) < 0.0001
Adjusted model 1
 Albumin 0.71 (0.56, 0.90) 0.005
Adjusted model 2
 Albumin 0.77 (0.60, 0.97) 0.03
 Body fat percentage 1.49 (1.12, 1.98) 0.007
Adjusted model 3
 Albumin 0.74 (0.57, 0.95) 0.02
 Body fat percentage 1.22 (0.88, 1.69) 0.24
 M (log) 0.39 (0.28, 0.55) < 0.0001
 AIR (log) 0.64 (0.53, 0.77) < 0.0001
Adjusted model 4
 Albumin 0.75 (0.58, 0.96) 0.02
 Body fat percentage 1.26 (0.91, 1.77) 0.17
 M (log) 0.47 (0.32, 0.68) < 0.0001
 AIR (log) 0.71 (0.53, 0.78) 0.0007
 FPG 0.99 (0.77, 1.28) 0.93
 2-h PG 1.38 (1.09, 1.75) 0.007
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